An interventional study of HPV MISTICS -Provider Level and HPV MISTICS - Parent Level in Human Papilloma Virus (HPV) Vaccine, sponsored by H. Lee Moffitt Cancer Center and Research Institute. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by H. Lee Moffitt Cancer Center and Research Institute · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 166 studies in Papillomavirus Infections with a site in United States — 32 open to participants now, 60 under way, 5 of them phase 3. Papillomavirus Infections · United States.
Among the 166 studies in Papillomavirus Infections with a site in United States, this one is the 63rd largest by enrollment of the 132 interventional ones that give a count, is one of 14 that started in 2023, is one of 53 with no phase, reaches primary completion later than 18 of the 59 other live ones, and was the 125th registered.
581 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.
Browse Papillomavirus Infections studies →32 of the 166 studies in Papillomavirus Infections with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 18+
Daré Bioscience, Inc. · Sites in United States
Ages 22–50 · Women only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Women only
Washington University School of Medicine · Sites in United States
Ages 25+ · Women only · Healthy volunteers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Papillomavirus Infections studies recruiting now, 40 (45%) set no upper age limit and 44 (49%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
166 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 48 · Phase 3 18 · Phase 4 8
First in 2003; this study’s year is marked. 14 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is below the median of 229 across 406 interventional studies indexed under Papillomavirus Infections.
Median enrollment 128 across the 132 interventional studies, 197 across the 33 observational. Of the 95 that completed or were terminated, 47 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 166 have an industry lead sponsor. The 10 most frequent:
H. Lee Moffitt Cancer Center and Research Institute is the lead sponsor of 542 studies on the registry; 77 are open to participants now.
Of its 99 completed or terminated interventional studies of FDA-regulated products, 57 (58%) have results posted.
H. Lee Moffitt Cancer Center and Research Institute has 2 studies filed under Papillomavirus Infections — fewer than ten, so there is no comparison to draw.
29 of the studies in Papillomavirus Infections with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217145Phase 3University of UtahPREVENT HPV -Related Cancers Trial | 2026-11 |
| NCT04199689Phase 3Merck Sharp & Dohme LLCEfficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | 2027-01-15 |
| NCT04965792Dana-Farber Cancer InstitutePost-treatment Surveillance in HPV+ Oropharyngeal SCC | 2026-11 |
| NCT04206813Boston Medical CenterAn Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen | 2026-12 |
| NCT05677360H. Lee Moffitt Cancer Center and Research InstituteHPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS) | 2026-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 166 studies in Papillomavirus Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This intervention study will use parent-, provider-, and health center-level strategies to promote HPV vaccination among 11-17 year olds receiving care in 8 community health centers in Florida, will explore factors related to the intervention effect, and will explore implementation outcomes of the intervention.
The goals of this multi-level intervention study are to: 1) test whether HPV MISTICS intervention increases human papillomavirus (HPV) vaccine initiation and completion rates among 11-17-year-old adolescents in 8 Health Choice Network-affiliated community health centers in Florida. 2) Explore other factors related to the intervention effect. 3) Explore implementation outcomes (i.e., reach, adoption, implementation, maintenance, and sustainability) and identify implementation barriers and facilitators with a focus on equity. The study will use parent-, provider-, and health center-level strategies to promote HPV vaccination.
Inclusion Criteria:
Initial group of community health centers to receive intervention
Behavioral: HPV MISTICS -Provider Level · Behavioral: HPV MISTICS - Parent Level · Behavioral: HPV MISTICS- HPV Vaccine Champion Level
Second group of community health centers to receive intervention
Behavioral: HPV MISTICS -Provider Level · Behavioral: HPV MISTICS - Parent Level · Behavioral: HPV MISTICS- HPV Vaccine Champion Level
The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) provider-level intervention for all clinical staff (e.g., physicians, nurses, medical assistants) includes a 1-hour online training session on the Announcement Approach (i.e., presumptive recommendation) to recommend adolescent vaccinations.
The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) parent-level intervention includes a low literacy pre-visit HPV vaccine notification post card in the parent's preferred language.
The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) system-level intervention involves training an HPV Vaccine Champion at each FQHC on the provider and parent EBIs to monitor and share clinic HPV initiation and completion rates with providers, and to implement reminder/recall systems for subsequent vaccine doses
Effectiveness: HPV Vaccine series initiation rates
HPV vaccine series initiation (1st dose) rates among adolescents ages 11-17 will be determined on a monthly basis as well as annually. Providers' vaccination rate data for their patient panel (using Florida SHOTS - a free, statewide centralized online immunization information system) will be compared to the National Immunization Survey-Teen (NIS-TEEN) data for the state of Florida.
Time frame: at 5 years
Effectiveness: HPV Vaccine series completion rates
HPV vaccine series completion (2nd and 3rd dose) rates among adolescents ages 11-17 will be determined on a monthly basis as well as annually. Providers' vaccination rate data for their patient panel (using Florida SHOTS - a free, statewide centralized online immunization information system) will be compared to the National Immunization Survey-Teen (NIS-TEEN) data for the state of Florida.
Time frame: at 5 years
Implementation outcome: Reach
The intervention's implementation will be evaluated for reach - proportion of eligible patients that receive the intervention.
Time frame: at 5 years
Implementation outcome: Reach demographics
The intervention's implementation will be evaluated for reach - demographics of patients reached.
Time frame: at 5 years
Proportion of Healthcare providers who participate in the intervention
The proportion of health care providers who participate in the intervention, measured by contact log data.
Time frame: at 5 years
Proportion of Healthcare Providers, Rural vs Urban
The proportion of health care providers in rural vs urban Federally Qualified Health Centers in network that participate.
Time frame: at 5 years
Proportion of Health Care providers who complete training
The proportion of participating health care providers and staff who complete training per site will be measured using the training attendance log
Time frame: at 5 years
Intervention Sustainability: Health care Providers
Long term intervention effects and use over time will be determined semi-structured interviews of providers
Time frame: at 5 years
Intervention Sustainability: Healthcare staff
Long term intervention effects and use over time will be determined semi-structured interviews of health care staff.
Time frame: at 5 years
Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.
Of 110 non-industry interventional studies with no phase under Papillomavirus Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 47 months is above that.
Counting every sponsor, half of 119 studies reached it within 26 months; a quarter within 10 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
H. Lee Moffitt Cancer Center and Research Institute →